Active, not recruitingPHASE1, PHASE2NCT05025800
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Studying Composite lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Paolo Strati, MDM.D. Anderson Cancer Center
- Intervention
- CD47 Antagonist ALX148(drug)
- Enrollment
- 47 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05025800 on ClinicalTrials.gov